Intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: A subgroup analysis from the FLASH-UK study.
continuous blood glucose monitoring
deprivation
insulin
type 1 diabetes
Journal
Diabetic medicine : a journal of the British Diabetic Association
ISSN: 1464-5491
Titre abrégé: Diabet Med
Pays: England
ID NLM: 8500858
Informations de publication
Date de publication:
28 Oct 2023
28 Oct 2023
Historique:
revised:
19
10
2023
received:
24
08
2023
accepted:
20
10
2023
pubmed:
28
10
2023
medline:
28
10
2023
entrez:
28
10
2023
Statut:
aheadofprint
Résumé
The FLASH-UK trial showed lower HbA1c with intermittently scanned continuous glucose monitoring (isCGM), as compared with self monitoring of blood glucose (SMBG), in adults with type 1 diabetes and HbA1c ≥58 mmol/mol (≥7.5%). Here, we present results from the pre-specified subgroup analysis for the 24-week HbA1c (primary outcome) and selected sensor-based secondary outcomes. This was a multi-centre, parallel-design, randomised controlled trial. The difference in treatment effect between subgroups (baseline HbA1c [≤75 vs. >75 mmol/mol] [≤9.0 vs >9.0%], treatment modality [pump vs injections], prior participation in structured education, age, educational level, impaired awareness of hypoglycaemia, deprivation index quintile sex, ethnic group and Patient Health Questionnaire-9 [PHQ-9] detected depression category) were evaluated. One hundred fifty-six participants (females 44%, mean [SD] baseline HbA1c 71 [9] mmol/mol 8.6 [0.8%], age 44 [15]) were randomly assigned, in a 1:1 ratio to isCGM (n = 78) or SMBG (n = 78). The mean (SD) baseline HbA1c (%) was 8.7 (0.9) in the isCGM group and 8.5 (0.8) in the SMBG group, lowering to 7.9 (0.8) versus 8.3 (0.9), respectively, at 24 weeks (adjusted mean difference -0.5, 95% confidence interval [CI] -0.7 to -0.3; p < 0.001]. For HbA1c, there was no impact of treatment modality, prior participation in structured education, deprivation index quintile, sex or baseline depression category. The between-group difference in HbA1c was larger for younger people (a reduction of 2.7 [95% CI 0.3-5.0; p = 0.028] mmol/mol for every additional 15 years of age). Those with HbA1c 76-97 mmol/mol (>9.0%-11.0%) had a marginally non-significant higher reduction in HbA1c of 8.4 mmol/mol (3.3-13.5) compared to 3.1 (0.3-6.0) in those with HbA1c 58-75 mmol/mol (p = 0.08). For 'Time in range' (% 3.9-10 mmol/L), the difference was larger for those with at least a bachelor's degree. For 'Time below range' (% <3.9 mmol/L), the difference was larger for those using injections, older people and those with less than bachelor's degree. Intermittently scanned continuous glucose monitoring is generally effective across a range of baseline characteristics.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15249Subventions
Organisme : Diabetes UK
Pays : United Kingdom
Informations de copyright
© 2023 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK.
Références
Daneman D. Type 1 diabetes. Lancet. 2006;367(9513):847-858.
Vincze G, Barner JC, Lopez D. Factors associated with adherence to self-monitoring of blood glucose among persons with diabetes. Diabetes Educ. 2004;30(1):112-125.
Moström P, Ahlén E, Imberg H, Hansson PO, Lind M. Adherence of self-monitoring of blood glucose in persons with type 1 diabetes in Sweden. BMJ Open Diabetes Res Care. 2017;5(1):e000342.
Foster NC, Beck RW, Miller KM, et al. State of type 1 diabetes management and outcomes from the T1D exchange in 2016-2018. Diabetes Technol Ther. 2019;21(2):66-72.
Avari P, Reddy M, Oliver N. Is it possible to constantly and accurately monitor blood sugar levels, in people with type 1 diabetes, with a discrete device (non-invasive or invasive)? Diabet Med. 2020;37(4):532-544.
Leelarathna L, Wilmot EG. Flash forward: a review of flash glucose monitoring. Diabet Med. 2018;35(4):472-482.
Wilmot EG, Evans M, Barnard-Kelly K, et al. Flash glucose monitoring with the FreeStyle Libre 2 compared with self-monitoring of blood glucose in suboptimally controlled type 1 diabetes: the FLASH-UK randomised controlled trial protocol. BMJ Open. 2021;11(7):e050713.
Leelarathna L, Evans ML, Neupane S, et al. Intermittently scanned continuous glucose monitoring for type 1 diabetes. N Engl J Med. 2022;387(16):1477-1487.
Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194.
Gov.uk. English Indices of Deprivation 2019. Ministry of Housing, Communities & Local Government; 2020. Accessed August 10, 2023. https://www.gov.uk/government/statistics/english-indices-of-deprivation-2019
Shah N, Deshmukh H, Wilmot EG, et al. Previous structured education attendance and the relationship with HbA1c and hypoglycaemia awareness in people living with type 1 diabetes mellitus using FreeStyleLibre: insights from the Association of British Clinical Diabetologists (ABCD) Nationwide Audit. Br J Diabetes. 2021;21(2):192-197.
Deshmukh H, Adeleke KA, Ssemmondo E, et al. Ethnic disparities in people accessing FreeStyle libre in the United Kingdom: insights from the Association of British Clinical Diabetologists audit. Diabet Med. 2023;40(8):e15095.
Deshmukh H, Wilmot EG, Gregory R, et al. Effect of flash glucose monitoring on glycemic control, hypoglycemia, diabetes-related distress, and resource utilization in the Association of British Clinical Diabetologists (ABCD) nationwide audit. Diabetes Care. 2020;43(9):2153-2160.
Deshmukh H, Wilmot E, Pieri B, et al. Time in range following flash glucose monitoring: relationship with glycaemic control, diabetes-related distress and resource utilisation in the Association of British Clinical Diabetologists national audit. Diabet Med. 2022;39(11):e14942.
Jeyam A, Gibb FW, McKnight JA, et al. Flash monitor initiation is associated with improvements in HbA1c levels and DKA rates among people with type 1 diabetes in Scotland: a retrospective nationwide observational study. Diabetologia. 2022;65(1):159-172.
Visser MM, Charleer S, Fieuws S, et al. Comparing real-time and intermittently scanned continuous glucose monitoring in adults with type 1 diabetes (ALERTT1): a 6-month, prospective, multicentre, randomised controlled trial. Lancet. 2021;397(10291):2275-2283.
Visser MM, Charleer S, Fieuws S, et al. The impact of baseline user characteristics on the benefits of real-time versus intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: moderator analyses of the ALERTT1 trial. J Diabetes Sci Technol. 2022;193229682211283. doi:10.1177/19322968221128315